Is Aurinia Pharmaceuticals' Management Its Best Asset?
Richard Glickman was the founder and CEO of Aspreva Pharmaceuticals, a small company that he sold for $915 million in 2008 after it developed CellCept, a treatment that today is commonly used in lupus nephritis (LN) patients.
Nowadays, Glickman's at it again as the founder and CEO of Aurinia Pharmaceuticals (NASDAQ: AUPH), a company that's developing voclosporin, a drug that can be used alongside CellCept in the same disease. Can Glickman reshape this indication a second time?
Source: Fool.com
Aurinia Pharmaceuticals Inc. Stock
€4.82
3.390%
The community is currently still undecided about Aurinia Pharmaceuticals Inc. with 0 Buy predictions and 1 Sell predictions.
However, we have a potential of 107.64% for Aurinia Pharmaceuticals Inc. as the target price of 10 € is above the current price of 4.82 €.
